Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.Researcher index
Authors in the psilocybin and psilocin literature
Search researcher names, inspect publication history, find recurring topics, and create author watch alerts without collecting unverified contact lists.
Publication history
Mindfulness-Based Psilocybin-Assisted Therapy (MB-PAT) for cancer-related demoralization in Canada: The case for a hybrid group-based delivery modelPsychedelics · 2026-12-01Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depressionJournal of Affective Disorders · 2026-11-01Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in ratsPharmacology Biochemistry and Behavior · 2026-10-01Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. AdultsAmerican Journal of Preventive Medicine · 2026-10-01Single-crystal structure determination of psilocybin after dehydrationActa Crystallographica Section C Structural Chemistry · 2026-09-01Assessing The Readiness of Psychiatrists in Louisiana to Incorporate Psilocybin into Clinical Practice-Lessons Learned from a State Underrepresented in Clinical Psychedelic Research.Psychedelic medicine (New Rochelle, N.Y.) · 2026-09-01A Nature-Themed Video Intervention Increases Nature Relatedness in Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder.Psychedelic medicine (New Rochelle, N.Y.) · 2026-09-01Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study.Psychedelic medicine (New Rochelle, N.Y.) · 2026-09-01Contribution of the Serotonin 5-HT2A Receptor to the Therapeutic Effect of Psilocin on Social Behavior Deficits in Mice Repeatedly Exposed to Social Defeat StressNeuropsychopharmacology Reports · 2026-09-01Balancing safety and access in Oregon’s psilocybin servicesInternational Journal of Drug Policy · 2026-09-01Genome-based optimization of psilocybin and N,N-dimethyltryptamine biosynthetic pathways in E. coli using CRISPR-associated transposasesMetabolic Engineering · 2026-09-01The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young AdultsClinicalTrials.gov · 2026-08-14Safety for Home Administration of Microdose Psilocybin UseClinicalTrials.gov · 2026-08-14Psilocybin Administration With 5-HT1a BlockadeClinicalTrials.gov · 2026-08-14A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in VeteransClinicalTrials.gov · 2026-08-14Ayahuasca and Salvia divinorum as contrasting modes of consciousness reorganization: Implications for psychedelic-assisted psychotherapyJournal of Psychedelic Studies · 2026-08-13Role of Experience, Conscious Awareness, and Plasticity in Psilocybin's Behavioral Effects - Follow-Up Study (The RECAP 2 Study)ClinicalTrials.gov · 2026-08-13Processing Intergenerational Trauma With Psilocybin-Assisted TherapyClinicalTrials.gov · 2026-08-13The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive DisorderClinicalTrials.gov · 2026-08-13PsiloStudy: A Phase 2 Single-site, Double-blind, Placebo-controlled, Randomized Clinical Trial With an Open-label Extension Phase to Examine the Safety, Subjective Experiences, Acute Effects, and Suitability of Psilocybin Combined With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring Alcohol Use Disorder (AUD) and Posttraumatic Stress Disorder (PTSD)ClinicalTrials.gov · 2026-08-13Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder: A Double-Blind, Dose-Comparison Concurrent Control Randomized TrialClinicalTrials.gov · 2026-08-13Psychedelic integration beyond the verbal: participatory-imaginal processing as a hypothesis-generating therapeutic frameworkFrontiers in Psychiatry · 2026-08-12Exploring the In Vitro Effect of Psilocybin on the Composition and Metabolic Activity of Gut Microbiota in Individuals with Severe AnxietyDrugs and Drug Candidates · 2026-08-12Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025-2026)Journal of Clinical Medicine · 2026-08-12TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance TherapyClinicalTrials.gov · 2026-08-12TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer SurvivorsClinicalTrials.gov · 2026-08-12Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use DisorderClinicalTrials.gov · 2026-08-12Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and SuicidalityClinicalTrials.gov · 2026-08-12Low-Dose Psilocybin Therapy for Palliative Care Patients With Chronic Cancer Pain Requiring OpioidsClinicalTrials.gov · 2026-08-12NeuroGuard: Psilocybin Trial for Preventing Chemo-induced NeuropathyClinicalTrials.gov · 2026-08-12A Phase 2a, Placebo-Controlled Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety DisorderClinicalTrials.gov · 2026-08-12Psychedelic Therapy for DepressionUnknown journal · 2026-08-11Psilocybin Recovery Intervention for Stopping Methamphetamine UseClinicalTrials.gov · 2026-08-11Effects of Psilocybin in Patients With Amyotrophic Lateral SclerosisClinicalTrials.gov · 2026-08-11Could Psilocybin Be the Key to Treating Anorexia? -Breaking the Mind's Most Stubborn LoopUnknown journal · 2026-08-10An Open-Label Trial Protocol to Test Menstrual Cycle Effects and Tolerance to Low-Dose Psilocybin in Healthy Menstruating Persons.Pharmacology · 2026-08-10An Investigation of Strategies to Understand and Optimize the Antidepressant Effects of Psilocybin (The OPTIMIZE Study)ClinicalTrials.gov · 2026-08-10A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10Safety, Tolerability, Outcomes of Psilocybin for Depression (STOP Depression) in Veterans With Spinal Cord InjuryClinicalTrials.gov · 2026-08-10A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older AdultsClinicalTrials.gov · 2026-08-10Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot StudyClinicalTrials.gov · 2026-08-10'So many relationships in the room': Participant perspectives on the affordances and challenges of co-therapy in psychedelic assisted therapy.Psychology and psychotherapy · 2026-08-10Advanced research eyes potential of psychedelics for complex casesMental Health Weekly · 2026-08-07Feasibility and Tolerability of Psilocybin for Phantom Limb Pain.The journal of pain · 2026-08-07Impact of Psilocybin on Motor Function in Healthy Participants: A Phase 1, Randomised, Triple-Blind, Dose-Finding Study.CNS drugs · 2026-08-07Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (NECTAR) in Aging and Alzheimer's DiseaseClinicalTrials.gov · 2026-08-07The Efficacy of Psilocybin Therapy for Depression in Parkinson's DiseaseClinicalTrials.gov · 2026-08-07Open Label Psilocybin Brain Stimulation and Imaging Pilot StudyClinicalTrials.gov · 2026-08-07Therapeutic potential of classic and non-classic psychedelics in neurodevelopmental disorders: Opportunities and challenges.Pharmacological research · 2026-08-06Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial.Nature medicine · 2026-08-06Single Dose Psilocybin for a Post-surgical Trauma Inpatient Population for Pain, Mood, and Opioid Use DisorderClinicalTrials.gov · 2026-08-06Psilocybin for Treatment-Resistant Depression in Autism: a Pilot Trial With Pre-Post Brain and Cognitive Measurement to Understand MechanismClinicalTrials.gov · 2026-08-06An Exploratory Study of Feasibility, Efficacy, and Mechanisms of Mindfulness-Assisted Psychedelic TherapyClinicalTrials.gov · 2026-08-06A suite of engineered mice for interrogating psychedelic drug actions.Nature neuroscience · 2026-08-06Role of β-Arrestin2 Signaling in Neuropharmacological Effects of Psychedelic Drugs.ACS chemical neuroscience · 2026-08-05Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced CancerClinicalTrials.gov · 2026-08-05Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic TherapiesClinicalTrials.gov · 2026-08-04Psychedelics and women's mental health: the effects of female sex hormones on psychedelics' efficacy and tolerability.Molecular psychiatry · 2026-08-04Serotonergic psychedelics induce distinct patterns of metabolic activity and covariance within biologically informed rat brain networksNature Communications · 2026-08-03Safety and Efficacy of Psilocybin During Anticancer Treatment: A Phase II Trial Secondary Analysis.Journal of pain and symptom management · 2026-08-03Psilocybin as a Treatment for Chronic Pain in SmokersClinicalTrials.gov · 2026-08-03Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility StudyClinicalTrials.gov · 2026-08-03Evaluating psilocybin for the management of depression: a literature reviewBritish Journal of Mental Health Nursing · 2026-08-02Psilocybin for Fear of Cancer RecurrenceSupportive Care in Cancer · 2026-08-01One Dose of Psilocybin May Alter Brain StructurePsychiatric News · 2026-08-01From trial to clinic: psilocybin's efficacy in routine treatment-resistant depression.The Lancet regional health. Europe · 2026-08-01In-silico toxicity study of tryptamine, psilocin, psilocybin, N,N-dimethyltryptamine, 5’-methoxy-N,N-dimethyltryptamine and O-acetylpsilocinArchives of Toxicology · 2026-08-01Psilocybin induces stereotyped movements and reduces defensive responding in planarians through 5-hydroxytryptamine mechanismsBehavioural Pharmacology · 2026-08-01Classic Psychedelics for Chronic Pain: A Critical Review of the Literature and Practical Advice for Clinicians.Drugs · 2026-08-01Current status and future prospects of research on psilocybin's regulation of neurotransmitters and their receptors related to the pathogenesis of tinnitus.Hearing research · 2026-08-01Pharmacokinetic and pharmacodynamic rational for expanding the therapeutic landscape of psilocybin beyond depressionPharmacological Research · 2026-08-01Anxiety-related platform in zebrafish (Danio rerio) larvae: An integrated analysis of behavioural and molecular assay in drug screening research.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026-08-01Psilocybin-assisted therapy for major depressive disorder: Perspective from meta-analysisJournal of Affective Disorders · 2026-08-01The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysisJournal of Affective Disorders · 2026-08-01A cross-national comparison of nonmedical and medical use of psychedelic drugs in the international cannabis policy study.The International journal on drug policy · 2026-08-01The Experience-Trajectory Framework: Substance-Specific Risk Stratification for Psychedelic Preparation and Aftercare Beyond Set and SettingInternational Journal For Multidisciplinary Research · 2026-07-31A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and DepressionClinicalTrials.gov · 2026-07-31Retreat from racism: A psychedelic group experience for racial stress and traumaPsychedelics · 2026-07-30Shrooming Ahead: How the U.S. is Marching Toward Psilocybin Legalization and What Other Countries May LearneYLS (Yale Law School) · 2026-07-30Childhood trauma and psychological outcomes following psychedelic use: a scoping reviewnpj Mental Health Research · 2026-07-30Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant DepressionClinicalTrials.gov · 2026-07-30Trauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for Post-Traumatic Stress DisorderClinicalTrials.gov · 2026-07-30Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trialCommunications Medicine · 2026-07-30Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)ClinicalTrials.gov · 2026-07-30Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND): An Open-Label Clinical TrialClinicalTrials.gov · 2026-07-30Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression: A Pilot Randomized Clinical TrialClinicalTrials.gov · 2026-07-30Psilocybin-containing mushroom-assisted psychotherapy is associated with sustained psychological and somatic improvements: two case studies from JamaicaFrontiers in Psychiatry · 2026-07-29An Open-Label, Phase 1 Study of the Safety Pharmacokinetic Profile, and Preliminary Efficacy, of Organic Whole Psilocybin-Containing Mushrooms in Patients Suffering From PTSDClinicalTrials.gov · 2026-07-29Activating Neuroplasticity to ENHANCE the Perception Box Expanding Effects of PsilocybinClinicalTrials.gov · 2026-07-29Is BOLD Measurement-Invariant Across Pharmacological State? A Pre-Registered Test of Haemodynamic Response Function Drug-Invariance Using Simultaneous EEG-fMRI (PsiConnect)Open MIND · 2026-07-28Convergent neuroimmune signaling underlying rapid antidepressant response to ketamine and psychedelics.Molecular psychiatry · 2026-07-28Changes in Self-awareness Induced by Psychoactive Substances: an Experimental Study With Psilocybin.ClinicalTrials.gov · 2026-07-28Long- term administration of low doses of psilocybin causes epigenetic changes in the rat medial prefrontal cortexPsychopharmacology · 2026-07-28Evaluating the Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant Obsessive-compulsive Disorder: An Open-label Clinical TrialClinicalTrials.gov · 2026-07-28A Systematic Review of EEG Predictors and Correlates of Psilocybin’s Treatment in DepressionUndergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · 2026-07-27Integration in classic psychedelic-assisted therapies for mental health conditions: A scoping reviewPsychedelics · 2026-07-26Participants' Music Experiences Associated With Psychedelic-Assisted Psychotherapy for Life-Threatening Illness: Interpretivist Research.Journal of music therapy · 2026-07-24An Examination of Psilocybin Effects on Biomarkers of Longevity, Healthy Aging, and Purpose in LifeClinicalTrials.gov · 2026-07-24Psilocybin and Affective Function in Chronic Lower Back Pain DepressionClinicalTrials.gov · 2026-07-24Comparing synthetic and biological therapy for the treatment of cluster headache: what is needed and when?Expert review of neurotherapeutics · 2026-07-23No evidence for deleterious effects of psilocybin and MDMA on working memory or related neurophysiological activity in a non-clinical population: An uncontrolled exploratory studyJournal of Psychopharmacology · 2026-07-23A Randomized Double-masked Dose-controlled Trial to Assess the Tolerability, Safety, Subjective Experience, and Efficacy of Repeated Administration of Three Different Doses of Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.ClinicalTrials.gov · 2026-07-23Effects of Psilocybin on Electrophysiology and the Dynamic Content of ThoughtClinicalTrials.gov · 2026-07-23Probing the Functional Magnetic Resonance Imaging Response to Psilocybin in Functional Neurological Disorder (PsiFUND)ClinicalTrials.gov · 2026-07-23A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)ClinicalTrials.gov · 2026-07-23A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe AnxietyClinicalTrials.gov · 2026-07-23Longitudinal neural and psychological changes following psilocybin under compassion imagery primingFrontiers in Human Neuroscience · 2026-07-22PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin PretreatmentClinicalTrials.gov · 2026-07-21Psilocybin-Assisted Therapy for Physician Well-Being and Burnout: Feasibility, Safety, Clinical Effectiveness and Biomarkers of Response [PAT-B (Psilocybin-Assisted Therapy for Physician Well-Being and Burnout)]ClinicalTrials.gov · 2026-07-21The Efficacy of Psilocybin Therapy for Depression in Parkinson's DiseaseClinicalTrials.gov · 2026-07-20Learnings from a hybrid communities of practice group therapy model to support psilocybin-assisted therapy for patients with a terminal diagnosisFrontiers in Public Health · 2026-07-20Psilocybin produces amplified acute responses and sex-specific long-term increases in sensorimotor gating in the mGlu5 knockout mouse model of schizophreniaNeuropsychopharmacology · 2026-07-18Beyond Monoamines: Ketamine, Esketamine, and Classic Psychedelics in the Treatment of DepressionZenodo (CERN European Organization for Nuclear Research) · 2026-07-17A Randomized, Double-Blind, Single Ascending Dose Study to Identify a Safe and Non-Psychedelic Dose of PsilocybinClinicalTrials.gov · 2026-07-17Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind TrialClinicalTrials.gov · 2026-07-17Psychedelic Therapies in the Management of Post-Traumatic Stress DisorderJournal of Education Health and Sport · 2026-07-16Silence is golden: Documenting the speech production of participants and support providers in psilocybin administration sessions for the treatment of post-traumatic stress disorderJournal of Psychopharmacology · 2026-07-16Psilocybin in Chronic Low Back Pain: An Integrative Study of Lab-Based Mechanisms and Real-World Physical Therapy OutcomesClinicalTrials.gov · 2026-07-16Psilocybin's effect on human brain synaptic plasticity.Translational psychiatry · 2026-07-15Shurooms: The First Ethnomycological Study from Within the African Initiatory Tradition - Ewe, Soma, and the Ceremonial Architecture of Psilocybin Healing (N = 300+)Zenodo (CERN European Organization for Nuclear Research) · 2026-07-14Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Trauma-Related Major Depressive Disorder: Randomized Controlled TrialClinicalTrials.gov · 2026-07-14Reporting practices in psilocybin-assisted therapy trials for depression: A descriptive review and temporal overviewJournal of Psychedelic Studies · 2026-07-13Mechanistic Studies of Psilocybin in Headache DisordersClinicalTrials.gov · 2026-07-13Psilocybin-induced behavioral and cellular effectsJournal of Neurogenetics · 2026-07-12National bill seeks to jump-start psychedelic treatment for veteransAlcoholism & Drug Abuse Weekly · 2026-07-11Psilocybin bei Depression: Systematisches Review und Meta-Analyse zur antidepressiven WirksamkeitOSF · 2026-07-10Psychedelics produce enduring enhancement of reward responsiveness in male rats.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2026-07-10PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical TrialClinicalTrials.gov · 2026-07-10PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical TrialClinicalTrials.gov · 2026-07-10Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the BrainClinicalTrials.gov · 2026-07-10Therapeutic potential of psilocybin in the pharmacological treatment of obsessive-compulsive disorder: a scoping review protocol.Open MIND · 2026-07-09The Effects of Psilocybin on Social ConnectednessClinicalTrials.gov · 2026-07-09Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2)ClinicalTrials.gov · 2026-07-09Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic EffectsClinicalTrials.gov · 2026-07-09Psilocybin: Capturing Brain Mechanisms of Motivation and Neurocognition in Individuals With Opioid Use DisorderClinicalTrials.gov · 2026-07-09Entourage-Psilocybin-GanzpilzZenodo (CERN European Organization for Nuclear Research) · 2026-07-08Entourage-Psilocybin-GanzpilzZenodo (CERN European Organization for Nuclear Research) · 2026-07-08Psilocybin therapy for adult females with anorexia nervosa: pilot studyThe British Journal of Psychiatry · 2026-07-08Synthesis and Biological Evaluation of 4-Bromo-dimethyltryptamine (4-Br-DMT): A Synthetic Building Block for Future Analog Development.ACS omega · 2026-07-07α2-Adrenergic receptor modulates 5-HT2A-mediated behavioral effects of MDMA and psilocybin in miceMolecular Psychiatry · 2026-07-07CSF galanin and noradrenaline downregulation by psilocybin therapy in major depressive disorderNeuropsychopharmacology · 2026-07-07Caution in interpreting value-related change after psilocybin: Comment on Kerr-Gaffney et al. (2026)Journal of Psychopharmacology · 2026-07-07Phase I Study of the Safety and Adjunctive Effects of Psilocybin in Adults With Opioid Use Disorder Maintained on a Buprenorphine/Naloxone FormulationClinicalTrials.gov · 2026-07-07Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)ClinicalTrials.gov · 2026-07-07The need for another tool: Australian healthcare professionals on the use of psilocybin for existential distress in people with cancerBMC Medicine · 2026-07-06Psilocybe Poisoning: Pathophysiology, Classification and Treatment. A Clinical Case ReviewMexican Journal of Medical Research ICSA · 2026-07-05Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical DevelopmentBiomolecules · 2026-07-03Trajectories of psychedelic-assisted change: An observational study of a psilocybin retreat program followed by psychotherapeutic interventionsJournal of Psychedelic Studies · 2026-07-03Surprising Variability in Tryptamine Profiles of Fruiting Bodies: Inter- and Intra-Strain Differences Across 14 Strains Cultivated Under Controlled Conditions.Journal of fungi (Basel, Switzerland) · 2026-07-02Policy Considerations for Psychedelics in Research and Medicine - What’s Next on the Schedule?Journal of Science Policy & Governance · 2026-07-02Psilocybin as a Transdiagnostic Treatment for Eating Disorders and Comorbid Psychopathology: Implications for Clinical Nosology and Research DirectionsInternational Journal of Eating Disorders · 2026-07-02Consciousness and Psilocybin Effects on Well-Being: The CoPEWell StudyClinicalTrials.gov · 2026-07-02Unmixing the psychedelic connectome: Brain network traits of psilocybinNetwork Neuroscience · 2026-07-02Acceptability and safety of two sequential doses of psilocybin in bipolar II depression: protocol for an open-label single-arm feasibility studyBMJ Open · 2026-07-01Psilocybin helps woman with Alzheimer'sNew Scientist · 2026-07-01Convergent biosynthesis of psilocybin in an ectomycorrhizal lineage: is the psychoactive end-product the selected trait?EcoEvoRxiv · 2026-07-01Past-Year Psilocybin and Alcohol Co-Use: Associations With Mental Health SymptomsJournal of Drug Issues · 2026-07-01Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive SymptomsClinicalTrials.gov · 2026-07-01A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD)ClinicalTrials.gov · 2026-07-01Modeled Long-Term Effects of Psilocybin on Dynamic Activity and Effective Connectivity of Fronto-Striatal-Thalamic CircuitsHuman Brain Mapping · 2026-07-01Psilocybin-assisted therapy in treatment-resistant depression: rapid remission, uncertain durability, and the next phase of clinical evidenceAnnals of Medicine & Surgery · 2026-07-01An Open-Label Study of Single-Dose Psilocybin for Borderline Personality Disorder With Co-Occurring Major Depressive DisorderClinical Neuropharmacology · 2026-07-01Blinding Integrity in Psychedelic Randomized Clinical Trials: A Systematic Review.JAMA psychiatry · 2026-07-01Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholdersPalliative Medicine · 2026-07-01Psilocybin restores behavior and 5-HT2A signaling while reducing microglial density after chronic traumatic brain injury in ratsCell Reports Medicine · 2026-07-01The purpose of the psychosocial protocol in the psychedelic-assisted therapy: A scoping review.Journal of psychopharmacology (Oxford, England) · 2026-07-01Classical psychedelic microdosing, mood, and cognitive function: An umbrella review with narrative synthesis.Journal of psychopharmacology (Oxford, England) · 2026-07-01Psilocybin as a novel treatment for chronic pain.British journal of pharmacology · 2026-07-01The Australia story: Current status and future challenges for the clinical applications of psychedelics.British journal of pharmacology · 2026-07-01Neuropsychopharmacology of hallucinogenic and non-hallucinogenic 5-HT receptor agonists.British journal of pharmacology · 2026-07-01Psychedelics, entactogens and psychoplastogens for depression and related disorders.British journal of pharmacology · 2026-07-01Evidence that 5-HT receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non-psychedelic drugs.British journal of pharmacology · 2026-07-01Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?British journal of pharmacology · 2026-07-01Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology.British journal of pharmacology · 2026-07-01Psilocybin improves novel object recognition in a rat model of Fragile X Syndrome through the modulation of the BDNF/TrkB signaling pathway.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2026-07-01Recreational drug poisonings reported to six European poison centres from 2021 to 2024.Clinical toxicology (Philadelphia, Pa.) · 2026-07-01Three cases of wood-lover paralysis: clinical insights from Victoria, Australia.Clinical toxicology (Philadelphia, Pa.) · 2026-07-01Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participantsNeuropsychopharmacology · 2026-07-01Improving access to novel treatments for treatment-resistant depression: The potential role of specialist clinics in Australia.The Australian and New Zealand journal of psychiatry · 2026-07-01The relevance of the 5HT2A-mGlu2 heterodimer in explaining the clinical ambivalence of psilocybinRevista de Neuro-Psiquiatría · 2026-06-30Study Protocol for “Exploring the safety and therapeutic potential of psilocybin in the treatment of anorexia nervosa in adolescents and young adults”PLOS One · 2026-06-30Chemical ecology and convergent evolution of natural hallucinogens: From ecological defense to conserved neural targets.Proceedings of the National Academy of Sciences of the United States of America · 2026-06-30Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical DevelopmentUniversity of Groningen research database (University of Groningen / Centre for Information Technology) · 2026-06-295-HT2A Agonist Psilocybin in the Treatment of Tobacco Use DisorderClinicalTrials.gov · 2026-06-29Psilocybin reduces fear memory and restores neuroplasticity in the hippocampus and medial prefrontal cortexJournal of Psychopharmacology · 2026-06-28Psilocybin-Assisted Massed Cognitive Processing Therapy for Chronic Posttraumatic Stress Disorder: An Open-label TrialClinicalTrials.gov · 2026-06-26Anthracaurisin A─Discovery of a Cytotoxic -Sesquiterpene Dimer from Patagonian.Journal of natural products · 2026-06-26Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy SubjectsClinicalTrials.gov · 2026-06-25A Pilot Mechanistic RCT of Psilocybin With Mindfulness-based Therapy vs Support for Posttraumatic Stress Disorder (PTSD)ClinicalTrials.gov · 2026-06-25Multi-metric evaluations of acute psychedelic effects on fMRI brain entropy.Nature communications · 2026-06-24Psychedelics and autism spectrum disorder: Mechanistic insights, translational evidence and ethical challenges.Journal of psychiatric research · 2026-06-23Mechanistic insights toward dissociating therapeutic from psychedelic effects: bridging the gap between psychedelic research and mental health careTranslational Psychiatry · 2026-06-23Effects of Psilocybin Microdosing on Cognition, Mood and Quality of Life: A Pilot StudyClinicalTrials.gov · 2026-06-23Psilocybin-assisted Existential, Attachment and Relational (PEARL) Therapy for Caregivers of Patients With Advanced Cancer: A Phase II Open-Label TrialClinicalTrials.gov · 2026-06-23Psilocybin-Assisted Therapy for Prolonged GriefClinicalTrials.gov · 2026-06-23Blocking 5-HT2B receptors abolishes psilocybin's efficacy in the rat forced swim test.Journal of psychopharmacology (Oxford, England) · 2026-06-23Psilocybin for PTSD With or Without Psychotherapy: A Pilot Study of Safety and EfficacyClinicalTrials.gov · 2026-06-22Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Phase II Open-Label TrialClinicalTrials.gov · 2026-06-22Psychedelic Use, Microdosing, Motives, and Information and Product Sources Among Young Adults in the United States.Journal of psychoactive drugs · 2026-06-19